Riverbridge Partners LLC Has $46.37 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

Riverbridge Partners LLC lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 82,524 shares of the company’s stock after selling 7,175 shares during the quarter. IDEXX Laboratories comprises approximately 1.1% of Riverbridge Partners LLC’s holdings, making the stock its 29th largest holding. Riverbridge Partners LLC’s holdings in IDEXX Laboratories were worth $46,370,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of IDXX. SHP Wealth Management acquired a new stake in IDEXX Laboratories in the 4th quarter worth $26,000. Virtus Advisers LLC bought a new position in shares of IDEXX Laboratories during the 3rd quarter worth about $26,000. Park Place Capital Corp acquired a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $29,000. Mowery & Schoenfeld Wealth Management LLC raised its position in shares of IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 20 shares during the last quarter. Finally, Wormser Freres Gestion lifted its stake in shares of IDEXX Laboratories by 671.4% in the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 47 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $541.31 on Wednesday. The firm has a market cap of $42.70 billion, a P/E ratio of 39.86, a price-to-earnings-growth ratio of 2.99 and a beta of 1.55. The firm’s 50-day simple moving average is $560.45 and its 200-day simple moving average is $617.53. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on IDXX shares. Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price on the stock. UBS Group cut their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Finally, Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.